vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
13.48
-0.48 (-3.44%)
Jan 22, 2025, 4:00 PM EST - Market closed
vTv Therapeutics Employees
vTv Therapeutics had 16 employees as of December 31, 2023. The number of employees increased by 3 or 23.08% compared to the previous year.
Employees
16
Change (1Y)
3
Growth (1Y)
23.08%
Revenue / Employee
$62,500
Profits / Employee
-$1,144,125
Market Cap
43.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
VTVT News
- 6 weeks ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire
- 7 weeks ago - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold - GlobeNewsWire
- 7 months ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 8 months ago - CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING - PRNewsWire
- 9 months ago - vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 months ago - CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT - PRNewsWire